SCHEMBL6318213

SCHEMBL6318213

CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1cccc2ccccc12)N(C)C(=O)/C=C/CC(C)(C)N

nearest known ligand 0.71

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 8/20 0.49
HRH4 Q9H3N8 1/20 0.37
METAP2 P50579 1/20 0.36
MMP9 P14780 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6318847 1.00 GHSR (0.49) GHSRHRH4METAP2MMP9
SCHEMBL6319716 1.00 GHSR (0.49) GHSRHRH4METAP2MMP9
SCHEMBL7979458 1.00 GHSR (0.49) GHSRHRH4METAP2MMP9
SCHEMBL6320106 1.00 GHSR (0.49) GHSRHRH4METAP2MMP9
SCHEMBL6316681 0.92 GHSR (0.49) GHSRMMP9
SCHEMBL6325138 0.92 GHSR (0.49) GHSRMMP9
SCHEMBL6316698 0.92 GHSR (0.49) GHSRMMP9
SCHEMBL6325135 0.92 GHSR (0.49) GHSRMMP9
SCHEMBL6320802 0.92 GHSR (0.59) GHSRMMP9
SCHEMBL6323451 0.92 GHSR (0.59) GHSRMMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3765658-B1 ELECTROPLATED PRODUCTS AND ELECTROPLATING BATH FOR PROVIDING SUCH PRODUCTS COVENTYA S P A (IT) 2023-06-14 EP claimed
US-11142826-B2 Substitution-type electroless gold plating solution containing purine or pyrimidine-based compound having carbonyl oxygen and substitution-type electroless gold plating method using the same MK CHEM & TECH CO., LTD (KR) 2021-10-12 US claimed
EP-3765658-A1 ELECTROPLATED PRODUCTS AND ELECTROPLATING BATH FOR PROVIDING SUCH PRODUCTS COVENTYA S.p.A. (IT) 2021-01-20 EP claimed
US-20200095685-A1 SUBSTITUTION-TYPE ELECTROLESS GOLD PLATING SOLUTION CONTAINING PURINE OR PYRIMIDINE-BASED COMPOUND HAVING CARBONYL OXYGEN AND SUBSTITUTION-TYPE ELECTROLESS GOLD PLATING METHOD USING THE SAME MK CHEM & TECH CO., LTD (KR) 2020-03-26 US claimed
EP-3540097-A1 ELECTROPLATED PRODUCTS AND ELECTROPLATING BATH FOR PROVIDING SUCH PRODUCTS COVENTYA S.p.A. (IT) 2019-09-18 EP claimed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US claimed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US claimed
US-6194032-B1 ELECTROLESS PLATING MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2001-02-27 US claimed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 US claimed
WO-1999018255-A1 SELECTIVE SUBSTRATE METALLIZATION MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1999-04-15 WO claimed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP claimed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO claimed
US-5006208-A Galvanic gold alloying bath DEGUSSA AKTIENGESELLSCHAFT (DE) 1991-04-09 US claimed
JP-2054773-A None JP disclosed
JP-2070084-A None JP disclosed
JP-2054774-A None JP disclosed
US-4426442-A Method of producing metal images or patterns on and/or below the surface of a substrate comprising a semiconducting light-sensitive compound U.S. PHILIPS CORPORATION (US) 1984-01-17 US disclosed
EP-0094711-A1 Method of manufacturing finely structured metal patterns on metal or semiconductor surfaces Koninklijke Philips Electronics N.V. (NL) 1983-11-23 EP disclosed
EP-0070061-A1 A solution for the electroless deposition of gold-alloys onto a substrate Koninklijke Philips Electronics N.V. (NL) 1983-01-19 EP disclosed
US-4274926-A ALKALI METAL THIOCYANATE, OXIDATION RESISTANCE DEGUSSA AKTIENGESELLSCHAFT (DE) 1981-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 GHSR 2/4885HRH4 1267/4885METAP2 1489/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR GHSR 2/4885HRH4 976/4885METAP2 1495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.